Human Clinical Trial Of COVID-19 Vaccine "Covaxin" Begins At UP Hospital

Here's what Fauci thinks about the latest vaccine trial

The vaccine candidate in news has been developed by Moscow's Gamaleya Institute and the Russian Direct Investment Fund.

"We are energized to see these preclinical data simply because they clearly show our SARS-CoV-2 vaccine prospect generated a powerful antibody reaction and offered security with a solitary dose", explained Paul Stoffels, Johnson & Johnson's chief scientific officer.

Moreover, Russian drugmaker R-Pharm has signed a deal with AstraZeneca for it to manufacture a coronavirus vaccine being developed by the British pharmaceuticals giant and Oxford University, it said earlier.

Dmitriev likened what he said was Russia's success in developing a vaccine to the Soviet Union's 1957 launch of Sputnik 1, the world's first satellite.

Sputnik was the world's first satellite launched by Russian Federation in 1957.

Russian officials, as reported by CNN said that their scientific data is now being compiled and will be out for peer review and publication by early August.

"On Wednesday, we received the first consignment of 34 Covaxin developed by Bharat Biotech International and on Friday, we received 20 Covaxin developed by drug firm Zydus Cadila and we are expecting more vaccines from the companies soon", Mr Chaturvedi said.

"Our pre-clinical results give us reason to be optimistic as we initiate our first-in-human clinical trial, and we are excited to enter the next stage in our research and development toward a COVID-19 vaccine".

However, a number of global vaccines are already in the third phase of trials.

In recent months, Russian Federation has rushed to develop a vaccine against the coronavirus.

"A single-shot immunization has practical and logistical advantages over a two-shot regimen for global deployment and pandemic control, but a two-shot vaccine will likely be more immunogenic, and thus both regimens are being evaluated in clinical trials", Barouch added.

It says the vaccine prevented infection by providing complete or near-complete protection in the lungs from the virus in non-human primates in the pre-clinical study. Trials on its vaccine have also started in many countries.

The team also noted that the Ad26.COV2.S vaccine is on track to start a phase 3 efficacy trial in 30,000 participants in September.

Related:

Comments


Other news